About Protocadherin-23
Protocadherin-23 (DCHS2) is a protein
from Homo sapiens identified by UniProt accession
Q6V1P9, 3371 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Protocadherin-23 |
|---|
| UniProt accession | Q6V1P9 |
|---|
| Gene | DCHS2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3371 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (43)
Diseases linked to this target (Open Targets).
- fibrinogen measurement · score 0.33
- electrocardiography · score 0.33
- Graves disease · score 0.32
- thyrotoxic periodic paralysis · score 0.32
- appendicular lean mass · score 0.27
- fatty acid-binding protein, adipocyte measurement · score 0.25
- pituitary stalk interruption syndrome · score 0.19
- parental genotype effect measurement · score 0.15
- food allergy measurement · score 0.15
- multiple congenital anomalies/dysmorphic syndrome-intellectual disability · score 0.12
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3371 residues)
MSPCGRKMGE GRQQRRAPVG KLLLLPGRRD TPHGRSGSSG ARTQRSLLWL LVHVWLWAAS GSSAQLFNLT LSVDEGLPPD TLVGDIRAGL PAAQQQEGSG FFLSEDSDDS PLLDDFHVHP DTGIIRTARR LDRERRDHYS FVAATLLGAV VQVEIRVNDV NDHSPRFPLD SLQLDVSELS PPGTAFRLPV AHDPDAGLFS TQGYTLVQPS DLPKDPAGPF FQLRYRTPGP LPSPLLPGSS SPLEPLDLVL LRRLDREEAA AHRLQIEAWD GGRPRRTGLL SVELRVLDEN DNPPVFEQDE YRAAVREDAQ PGAEVCRVRA TDRDLGPNGF VRYSVRARQV PGAGSGGGAL GDAAYFAVEE LSGVVRVWRP LDREAQAWHQ LVVEARDGGA EPEVATVRVS IAVLDVNDNR PAIHVLFLTE GGVARVSEGA RPGDYVARVS VSDADGDWEK EDEATGELGV GLGDGSISLS LEGGEGDFAL LPGGPPGVFF LCVEGPLDRE SRDLYELLLV ATDAGSPPLS TEETLLLRVA DLNDQPPLFS QQHYKASVSE AAAPGTVVMW VSASDADEAG SDHAWLRYTV VQLSAPCNLG SLQSKMVHTA ECGPSFAIDS ESGAISTIRT LDREVQEAVE LKVVAQDLGE PPLSATCLVS ITVDDVNDNE PIFWRQVYNA TIAEHAPVGH CFLQVTASDA DSGLYGFIEY SLYDGFLSYE APQAFRIDPH DGQICVSQDI DRERDPATYD LLVEAKDGGG LSAQAFVRVD LEDVNDNHPV FNPSTYVTSI SDETQPGTEI INVLATDQDS GIYGTVAYEL IPGNVSSLFT IDSTTGIIYL TLPLSHLEST TLSLMVSAQD GGGLTAVINA DVTIHIFQTT LAPAEFERPK YTFLVYEDVP EDSPIGTVKA REPLNSSEPI FYRISSGDLG GKFSIHPRLG TIRTRKPLDH ETQPVVVLTV QAQLGSAPAC SSTEVNITVM DVNDNHPAFL RTSDEIRISQ TTPPGTALYL ARAEDRDSGR NGLIRYSIAS PQPGVFAIDR ALGVLFLNGS LGAGEQRELT LTLRAEDQGV HPQAALLVLT VVIEKREHSP SWTFEHLVYQ VEVSESLSPM TQMLQTQAHP LGPQRAASPL RYSLEPSVDS AMFGIRPYTG WIYLRRQFDY ESTQTYNFRV FAWIPEDGFL QNVSTTVIVR VWDENDNSPT FLHDVLFLKV EESPVPQGVI GKITAIDMDS GKNGQLLYFL LSDGKFFKMN PNTGELINWV ALDREHRGHH EMTVLVTDRG SPPRNATMAV YVSVTDINDN RPFFPQCLPG KELHVKVLEG QPVNMLVTTV FAKDPDEGNN AEVTYSVSSE DSSDHFKIDA NNGEIRTTTI LSYDYRPSYR MSVIATDQGV PPLQGQAVVN IQVIPLSKGR AIMSQNIRHL IIPENLKPTK IMSLIKSSDH LQQHYNGKLH FSIVADDKDG HFEIDSSTGD LFLSKELDYE TTSHYLFRVI TTDHSKNLSL SSTVFLSIDV EDQNDHSPSF QDELIVISVE ENVPIGTLVY VFNAKDDDGS FLNSRIQYYI ESHNPGTNPF LIHPSFGTLV TVSRLDRESI PTVILTVTAS DQAVNVTDRR LRSLTAQIVI LDVNDHNPTF ISFPNAHVKE DVTVGSLVHH ITAHDPDEGR NGKVTYSILS GNENMTFMLD ESSGLLTTTC PLDYEMKTQH ILTVLALDDG TPALSSSQTL TVTVLDVNDE APVFKQHLYE ASVKENQNPG EFVTRVEALD RDSGVNSKLQ FEIMPGASFE LFEINSDTGE VVTTTILDRE IQEVFTLRVL VRDGGFPSLS STTTILCTVE DENDHAPEFI VSSYDIEVLE NQEPEVVYTV LASDMDAGNN RAVEYHIIDG NTDECFTINE MSGELSTTRA LDREQISNFT LVILCSDLGD PPRSSVIHLQ VRVLDANDHS PSFPTLYYQS SVREDAEVGT VVLVLSAVDK DEGLNGQTEY FLTDEASGAF TIDPMSGTLK TSNTLDREAR SQHTFSAVAR DCSIQGSRST TVIIKVYVTD VNDNDPVLEQ NPFDVFLSPE SPTNQTTVIV RADDLDLGPN GTVVFSFAET QSMFSIDKYT GEIQFQQNPS SEYFPIWLQL KVTDQGIPAR TTTGLLVIHM EGEDVKISFS HHLYKGLVTE NCEAGTSIVT VKAFAPDSIQ DSMKYSIFSG NEDGVLSLCS KSGQLTVKEP KFLDFEVRNE VQLIVLAESS GHRAYCKVAV LIQDENDNSP CFEQSIYQAS VSESQLYNAH VIQVFATDLD SGLNGLIEYS ILSGNQEEAF QIDALSGVIT TKAILDYELT SSYSLIVQAT DKGMPRLSNT TVIKVQVTDI NDNAPAFLPS EAVEITEDSL PGVIVTHVSV HDVDLNSAFI FSFAKESNPG TKFAIDQNTG VVVLVKTLDF EEMTEYELLI QISDSVHYTE GALVVRVLDV NDNPPVFSQD FYQVTVPESI PVGYSVLTLS ATDLESNENI SYRILSSSKE FSIDPKNGTI FTISPVLLLD TISTTQFLVE ASDGGNPDLR ALTLVEIGIE DMNNYAPEFT VKSYNLSLSE DALVGSTLVT FSNIDHDWTR ENTYVEYSII SGNSQNNFHV ETKFFHSEYP YKQVGYLVLL HSLDREASAS HELVILASDS GCPPLSSTAV ISIQVLDVND NPPNFSSLSY HTHVKESTPL GSHITVVSAN DRDTGSHAEI IYNIISGNEK GHFYLEENTG VLYLIKPLDY EKMTKFTLTV QASDAEKKHF SFAVVFVSVL DDNDHAPQFM FSSFSCIVPE NLPISSTICS INALDFDAGP YGELTYSIVS PCFLTHGMSY DHDLFLIDPL TGDIHAKQIL DYENGNKYCL TVQAKDKGDA TASLVVWVDI EGIDEFEPIF TQDQYFFTLP EKNKDRQLIG RVEASDADAG IDGVILYSLG TSSPFFSVNK TNGNIYLIRA LPLIKSQLNK EDTLEMKIIA HSPKSDSKFA SCTVFVNVSF SSEGTPLAVF ASSFSISLVV SFLVFLILIC ILIVMILRHK QKDTINNYEE KKTSSLDADL RVTRDASVLK AFQKTDDCSN EVVPVDATPE WLSLISIMEK DIVNLYRHSN SSGHCSVEGE TAEDKEIQRI NEHPYRKCSD SALSDHESRV PDSGIPRDSD QLSCLSGETD VMVTAETAEA SQTFGEGDQG EGCSTTCAQN NVLPQTVQKR EAKESILADV RKESVFISGD QEVRCAALST QTTSDHDGKD NYHWNYLLSW EPKFQPLASV FNDIAKLKDE HLHMPGIPKE KKSFVFPPPL ITAVAQPGIK AVPPRMPAVN LGQVPPKHPR SPIPYHLGSL PEGMTPNFSP SLSLLTMQPP ALSPLLREGE LLGTHISGTC HELKAEDEVQ I
Explore Protocadherin-23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets